Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Study of Pirfenidone Modified-Release Tablets in Healthy Chinese Subjects
NCT06569381Phase 1Completed
- Sponsor
- Overseas Pharmaceuticals
- Start
- Sep 2024
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of pirfenidone in idiopathic pulmonary fibrosis (IPF) (2 arms), sponsored by Overseas Pharmaceuticals. Primary endpoints: Peak Plasma Concentration at 1 month, Area Under the Curve to Last Quantifiable Concentration at 1 month and 1 more. Started Sep 2024; status: completed.
02
Drugs
pirfenidone
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT06569381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06569381.